 Biotech stocks were quiet in the week ending Feb. 14 amid some data readouts at a couple of conferences and earnings news flow from smid-cap companies. The following are key biotech catalysts to look forward to for the unfolding week: Conferences 34th German Cancer Conference: Feb 19-22 in Berlin, Germany International Association For The Study of Lung Cancer, or IASLC, 2020 Targeted Therapies of Lung Cancer Meeting: Feb. 19-22 in Santa Monica, California Related Link: 13 Key NASH Drug Candidates To Watch For In A Potential 30-Billion Market PDUFA Dates The FDA will rule on Agile Therapeutics Incs NASDAQ: AGR hormonal contraceptive patch Twirla by the PDUFA action date of Sunday. After two rejections in the past, Twirla managed to snag a positive Adcom verdict in October 2019. Late Monday, the company said it has negotiated a 35-million loan facility that has increased expectations concerning a positive verdict. The FDA is scheduled to issue its verdict on Merck Co., Inc.s NYSE: MRK sBLAs for Keytruda dosing schedule updates. 